AstraZeneca's First-in-Class Trispecific Antibody AZD5492 Granted IND Approval in China for Relapsed or Refractory B-Cell Malignancies

Intelligent Finance APP learned on October 29 that the official website of the Center for Drug Evaluation (CDE) of the China National Medical Products Administration announced that AstraZeneca's (AZN.US) AZD5492 has been approved for clinical trials in China, intended for the treatment of relapsed or refractory B-cell malignancies. Public information shows that this is a CD20×TCR×CD8 trispecific antibody and a CD8-guided T-cell engager. This marks the first time this new drug candidate has been approved for clinical trials in China.

B-cell malignancies are a class of malignant diseases originating from B lymphocytes. B lymphocytes are a key component of the immune system, responsible for producing antibodies to combat foreign pathogens. When B cells undergo abnormal proliferation and uncontrolled differentiation, B-cell malignancies such as multiple myeloma and lymphoma may develop.